AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
CAMP4 Therapeutics Corporation Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00L2CHQ99
3.30▼ 0.09 (-2.65%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
—
Trading Information
Previous Close
3.39
Day's Range
3.21 – 3.39
52-Week Range
2.90 – 7.75
Volume
279.3K
Avg Volume
266.7K
Share Statistics
Shares Outstanding
Employees
48
Exchange
XNAS
Listed
2024-10-11
Share count as of August 12, 2026

CAMP4 Therapeutics Corporation Common Stock (CAMP) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about CAMP4 Therapeutics Corporation Common Stock (CAMP)
What is CAMP4 Therapeutics Corporation Common Stock's Market Cap?
CAMP4 Therapeutics Corporation Common Stock's Market Cap is $207.1M, based on as-reported figures from SEC (XBRL) filings.
What is CAMP4 Therapeutics Corporation Common Stock's Price / Sales?
CAMP4 Therapeutics Corporation Common Stock's Price / Sales is 49.1×, based on as-reported figures from SEC (XBRL) filings.
What is CAMP4 Therapeutics Corporation Common Stock's Revenue (TTM)?
CAMP4 Therapeutics Corporation Common Stock's Revenue (TTM) is $4.2M, based on as-reported figures from SEC (XBRL) filings.
What is CAMP4 Therapeutics Corporation Common Stock's Net Income (TTM)?
CAMP4 Therapeutics Corporation Common Stock's Net Income (TTM) is -$107.2M, based on as-reported figures from SEC (XBRL) filings.
What is CAMP4 Therapeutics Corporation Common Stock's EBITDA?
CAMP4 Therapeutics Corporation Common Stock's EBITDA is -$51.1M, based on as-reported figures from SEC (XBRL) filings.
What is CAMP4 Therapeutics Corporation Common Stock's Diluted EPS (TTM)?
CAMP4 Therapeutics Corporation Common Stock's Diluted EPS (TTM) is -1.71, based on as-reported figures from SEC (XBRL) filings.
What is CAMP4 Therapeutics Corporation Common Stock's EBITDA Margin?
CAMP4 Therapeutics Corporation Common Stock's EBITDA Margin is -1211.0%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · CAMPAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023
Revenue:
Research and collaboration revenue—
YoY growth+18.8%—-46.6%—
Operating Expenses:
Research and development—
General and administrative—
Total operating expenses—
% of revenue852.1%—3771.3%1817.1%
Loss from operations—
% of revenue-752.1%—-3671.3%-1717.1%
Other (expense) income, net:
Interest income—
Change in fair value of derivative tranche liability—
Other (expense) income———
Total other (expense) income, net—
Net loss
% of revenue-1884.8%—-11575.9%-1899.2%
Net loss per share attributable to common stockholders, basic (in dollars per share)—
Net loss per share attributable to common stockholders, diluted (in dollars per share)—